Can lurbinectedin be used with certain medications?

What medications can be used with lurbinectedin?

Lurbinectedin is metabolized mainly by the CYP3A4 enzyme. Drugs that strong inhibit or induce this enzyme change its blood levels and affect safety and efficacy. Strong CYP3A4 inhibitors such as ketoconazole, itraconazole, clarithromycin, ritonavir, and lopinavir increase lurbinectedin exposure and raise the risk of side effects. Strong CYP3A4 inducers such as rifampin, carbamazepine, phenytoin, and St. John's wort lower its effectiveness. Avoid these combinations whenever possible.

How do CYP3A4 modulators affect lurbinectedin dosing?

Moderate CYP3A4 inhibitors require a lurbinectedin dose reduction to 1.5 mg/m² every three weeks. Moderate CYP3A4 inducers may necessitate an earlier return to full 3.5 mg/m² dosing if the patient is already in a lower dose. Moderate examples include erythromycin, diltiazem, verapamil, and fluconazole.

Why are patients warned about grapefruit?

Grapefruit juice and grapefruit products also act as strong CYP3A4 inhibitors. Patients should avoid them entirely during treatment with lurbinectedin.

What happens if lurbinectedin meets a transporter-mediated drug?

Lurbinectedin is also a substrate of P-gp. Concurrent use of P-gp inhibitors such as amiodarone, cyclosporine, and quinidine increases its exposure. Avoid or monitor closely when the combination is unavoidable.

When does the lurbinectedin patent expire?

The compound patent expires in 2030. DrugPatentWatch.com